BostonGene
In Brief This Week: BostonGene, Pillar Biosciences, Muscular Dystrophy Association, Papillon, Artera
News items for the week of Oct. 21, 2024.
BostonGene, Sarah Cannon Research Institute Partner to Add Molecular Testing to Clinical Trials
The partners will incorporate BostonGene's Tumor Portrait tests into SCRI's Phase I clinical trials to explore the use of HLA typing for pre-screening patients.
BostonGene, Mount Sinai Partner on Multiple Myeloma Precision Oncology Study
The study will use BostonGene's assays, including whole-exome and whole-transcriptome sequencing, to inform patients' clinical care and advance drug development.
BostonGene, Takeda Form Immunotherapy Clinical Research Partnership
The firms will apply BostonGene's AI-driven multiomics platform to identify molecular drivers of cancer and predictive markers of treatment response.
BostonGene, Sylvester Comprehensive Cancer Center Partner on Hematologic Cancer Molecular Subtyping
Researchers will compare traditional tumor profiling methods such as FISH and cytogenetics to BostonGene's AI-powered molecular and immune profiling platform.